Novo Nordisk News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.10.18	Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm (GlobeNewswire)
20.09.18	Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes (GlobeNewswire)
20.08.18	Oral semaglutide provides superior HbA1c and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial (GlobeNewswire)
08.08.18	Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018 (GlobeNewswire)
28.06.18	Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3 (GlobeNewswire)
20.06.18	Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials (GlobeNewswire)
29.05.18	Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial (GlobeNewswire)
02.05.18	Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018 (GlobeNewswire)
24.04.18	Novo Nordisk A/S - Reduction of the share capital (GlobeNewswire)
26.03.18	FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaemia in the Tresiba® label (GlobeNewswire)
23.03.18	Ozempic® approved in Japan for the treatment of type 2 diabetes (GlobeNewswire)
22.03.18	Resolutions from the Annual General Meeting of Novo Nordisk A/S (GlobeNewswire)
26.02.18	Novo Nordisk A/S: Election of employee representatives to the Board of Directors of Novo Nordisk A/ (GlobeNewswire)
23.02.18	Notice for the Annual General Meeting of Novo Nordisk A/S (GlobeNewswire)
22.02.18	Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide (GlobeNewswire)
09.02.18	Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes (GlobeNewswire)
08.02.18	Novo Nordisk files annual report with the SEC (GlobeNewswire)
01.02.18	Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) (GlobeNewswire)
15.12.17	Ozempic® (semaglutide) recommended for approval by the European regulatory authorities (GlobeNewswire)
05.12.17	Ozempic® (semaglutide) approved in the US (GlobeNewswire)
21.11.17	Highlights to be presented at Novo Nordisk's Capital Markets Day 2017 (GlobeNewswire)
01.11.17	Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 (GlobeNewswire)
18.10.17	Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee (GlobeNewswire)
16.10.17	Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide (GlobeNewswire)
29.09.17	Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US (GlobeNewswire)
29.09.17	CHMP endorses Tresiba® label update in the EU - new label reflects significant reduction in the risk of severe hypoglycaemia (GlobeNewswire)
25.08.17	Victoza® approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events (GlobeNewswire)
16.08.17	Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 (GlobeNewswire)
15.08.17	Changes in Novo Nordisk Executive Management (GlobeNewswire)
09.08.17	Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 (GlobeNewswire)
27.07.17	Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events (GlobeNewswire)
10.01.17	Fiasp® (fast-acting insulin aspart) approved in Europe (GlobeNewswire)
05.12.16	Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes (GlobeNewswire)
29.11.16	Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial (GlobeNewswire)
21.11.16	Novo Nordisk receives US FDA approval for Xultophy® 100/3.6 (GlobeNewswire)
11.11.16	Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp® (fast-acting insulin aspart) for the treatment of diabetes (GlobeNewswire)
10.11.16	Novo Nordisk submits application in the EU for including data from the two SWITCH trials in Tresiba® label (GlobeNewswire)
28.10.16	Novo Nordisk increased adjusted operating profit by 7% in local currencies in the first nine months of 2016 (GlobeNewswire)
25.10.16	Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label (GlobeNewswire)
07.10.16	Novo Nordisk receives Complete Response Letter in the US for faster-acting insulin aspart (GlobeNewswire)
29.09.16	Novo Nordisk announces plans to reduce workforce by approximately 1,000 employees (GlobeNewswire)
23.09.16	Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba® label (GlobeNewswire)
02.09.16	FDA extends regulatory review period for IDegLira by three months (GlobeNewswire)
01.09.16	Lars Rebien Sørensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jørgensen appointed as successor (GlobeNewswire)
05.08.16	Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 2016 (GlobeNewswire)
24.05.16	IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee (GlobeNewswire)
20.05.16	FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide (GlobeNewswire)
16.05.16	Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of haemophilia B (GlobeNewswire)
29.04.16	Novo Nordisk increased adjusted operating profit by 10% in local currencies in the first quarter of 2016 (GlobeNewswire)
28.04.16	Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2016 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

06.11.24		Novo Nordisk-Aktie springt hoch: Abnehm- und Diabetesmittel florieren
21.10.24		Novo Nordisk-Aktie in Grün: Novo Nordisk erreicht Erfolg mit Diabetesmedikament Rybelsus
13.09.24		Novo Nordisk-Aktie gefragt: Abnehmspritze Liraglutid mindert Übergewicht auch bei Kindern
19.04.24		Novo Nordisk-Aktie etwas höher: Novo Nordisk hat Genehmigung deutsche Biotech-Firma Cardior zu kaufen
23.11.23		Novo Nordisk-Aktie freundlich: Pharmariese Novo Nordisk baut Produktion weiter aus
10.11.23		Novo Nordisk-Aktie stabil: Novo Nordisk stockt Kapazität in Dänemark kräftig auf
13.10.23		Novo Nordisk-Aktie steigt: Novo Nordisk optimistischer für laufendes Jahr
11.10.23		FMC-Aktien und Fresenius-Titel brechen ein: Studienerfolg von Novo Nordisk belastet

06.11.24

Novo Nordisk-Aktie springt hoch: Abnehm- und Diabetesmittel florieren

21.10.24

Novo Nordisk-Aktie in Grün: Novo Nordisk erreicht Erfolg mit Diabetesmedikament Rybelsus

13.09.24

Novo Nordisk-Aktie gefragt: Abnehmspritze Liraglutid mindert Übergewicht auch bei Kindern

19.04.24

Novo Nordisk-Aktie etwas höher: Novo Nordisk hat Genehmigung deutsche Biotech-Firma Cardior zu kaufen

23.11.23

Novo Nordisk-Aktie freundlich: Pharmariese Novo Nordisk baut Produktion weiter aus

10.11.23

Novo Nordisk-Aktie stabil: Novo Nordisk stockt Kapazität in Dänemark kräftig auf